References
- Ettinger B. Optimal use ofpost-menopausalhorrnone replacement. Obstet Gynecol 1988;72:31S–36S
- Mackinlay SM, Brambilla PJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103–15
- Greendale GA, Lee NP, Arriola EA. The menopause. Lancet 1999;353:571–80
- Christiansen C, Christiansen MS, McNair P, et al. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273–9
- Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prey Med 1991;20:47–63
- Heimer G, Englund D. Estriol: absorption after long-term vaginal treatment and gastrointestinal absorption as influenced by meal. Acta Obstet Gynecol Scand 1984;63:563–7
- Henriksson L, Stjernquist M, Boquist L, et al. A comparative multi-center study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in post-menopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994;171: 624–32
- Nash HA, Alvarez-Sanchez F, Mishell DR, et al. Estradiol-delivering vaginal rings for hormone replacement therapy. Am J Obstet Gynecol 1999;181: 1400–6
- Englund DE, Viktor A, Johanssen EDB. Pharma-cokinetics and pharmacodynamic effects of vaginal estradiol administration from silastic rings in post-menopausal women. Maturitas 1981;3:125–33
- Stumpf P, Maruca J, Santen R, et al. Development of a vaginal ring for achieving physiologic levels of 1713-estradiol in hypo estrogenic women. J Clin Endo-crinol Metab 1982;54:208–10
- Stumpf P. Selecting constant serum estradiol levels achieved by vaginal rings. Obstet Gynecol 1986;67: 91–4
- Buckshee K, Koumar S, Saraya L. Contraceptive vaginal ring — a rising star on the contraceptive horizon. Adv Contracept 1990;6:177–83
- Roumen FJ, Dieben TO. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception 1999;59:59–62
- Weisberg E, Fraser FS, Mishell DR Sr, et al. A comparative study of 2 contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception 1999;59:305–10
- Vartiainen J, Wahlstrom T, Nilsson CG. Effects and acceptability of a new 1713-o estradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas 1993;17: 128–37
- Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262–7
- Smith DC, Prentice R, Thompson DJ, et al. Associa-tion of exogenous estrogen and endometrial carci-noma. N Engl J Med 1975;293:1164–7
- Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 1989;59:445–7
- Persson I, Adami H, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br J Med 1989;298:147–51
- Voight LF, Weiss NS, Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;1:274–7
- Menasahe Y, Judd HL. Estrogen—progestin replace-ment regimens. In Adashi EY, Rock JA, Rozenwaks Z, eds. Reproductive Endocrinology, Surgery and Techno-logy, Vol. 2. Philadelphia: Lippincott-Raven, 1996: 1760–73
- Barbieri RL. Endo metriosis and the estrogen threshold theory. Relation to surgical and medical treatment. J Reprod Med 1998;43:287–92